When drug value assessment meets real-world evidence: ICER enlists Aetion in pricing evaluation
In a union of two of the hottest trends in the US biopharma world, ICER is teaming up with a high-profile company to integrate real …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
